Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

MLA

David A. Palma, et al. “Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4–10 Oligometastatic Tumors (SABR-COMET-10): Study Protocol for a Randomized Phase III Trial.” BMC Cancer, vol. 19, no. 1, Aug. 2019, pp. 1–15. EBSCOhost, https://doi.org/10.1186/s12885-019-5977-6.

APA

David A. Palma, Robert Olson, Stephen Harrow, Rohann J. M. Correa, Famke Schneiders, Cornelis J. A. Haasbeek, George B. Rodrigues, Michael Lock, Brian P. Yaremko, Glenn S. Bauman, Belal Ahmad, Devin Schellenberg, Mitchell Liu, Stewart Gaede, Joanna Laba, Liam Mulroy, Sashendra Senthi, Alexander V. Louie, Anand Swaminath, … Suresh Senan. (2019). Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 19(1), 1–15. https://doi.org/10.1186/s12885-019-5977-6

Chicago

David A. Palma, Robert Olson, Stephen Harrow, Rohann J. M. Correa, Famke Schneiders, Cornelis J. A. Haasbeek, George B. Rodrigues, et al. 2019. “Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4–10 Oligometastatic Tumors (SABR-COMET-10): Study Protocol for a Randomized Phase III Trial.” BMC Cancer 19 (1): 1–15. doi:10.1186/s12885-019-5977-6.